Skip to content

Search across repositories

Find data for your analysis

602 datasets from 5 repositories. Filter by the analysis you need to run, not by what a repository says a dataset contains. How capability is measured.

62 of 602 datasets

  • Acute Myeloid Leukemia
    MixedProject-curated
    TARGET-AMLGDC2,492 casesMyeloid Leukemias, Not Applicable

    Why it fits: treatment response recorded; survival endpoints, median follow-up 3.5 years; 9 measurement types on the same cohort

    2,492 children and young adults with acute myeloid leukaemia - the largest paediatric cancer genomics cohort in this corpus, with 3.5 years of median follow-up and therapeutic agents recorded for 35% of cases.

    Clinical dataCopy numberDNA methylationmicroRNABulk RNA sequencingStructural variants+3 more

    137 articles analyzed these data - 695 cite the paper

  • CPTAC-Brain, Head and Neck, Kidney, Lung, Pancreas, Uterus
    Underused opportunityMixedProject-curated
    CPTAC-3GDC1,866 casesNot Applicable, Transitional Cell Papillomas and Carcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 22.9 months; 9 measurement types on the same cohort

    1,866 tumors across six cancer types with genomics in the GDC and proteomics in the PDC - the largest prospectively collected proteogenomic cohort, with recurrence recorded for 78% of cases.

    Copy numberDNA methylationmicroRNABulk RNA sequencingSingle-cell RNA sequencingStructural variants+3 more

    25 articles analyzed these data - 688 cite the paper

  • Molecular Profiling to Predict Response to Treatment for Acute Lymphoblastic Leukemia
    Underused opportunityMixedProject-curated
    MP2PRT-ALLGDC1,510 casesAcute Lymphoblastic Leukemia, Lymphoid Leukemias

    Why it fits: treatment response recorded; survival endpoints, median follow-up 8.3 years; 6 measurement types on the same cohort

    1,510 children with acute lymphoblastic leukaemia from Children's Oncology Group trials, with whole genome sequencing, 8.4 years of median follow-up, and a named treatment regimen and response recorded for every single case.

    Clinical dataCopy numberBulk RNA sequencingStructural variantsWhole genome sequencingWhole exome sequencing

    0 articles analyzed these data

  • Breast Invasive Carcinoma
    MixedProject-curated
    TCGA-BRCAGDC + IDC1,098 casesCystic, Mucinous and Serous Neoplasms, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.3 years; 12 measurement types on the same cohort

    1,098 breast tumors measured twelve ways across GDC and IDC, with treatment outcome on 64% of cases - the most reused dataset in this corpus and still the reference cohort for method development.

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    2,373 articles analyzed these data - 9,914 cite the paper

  • NCI Cancer Model Development for the Human Cancer Model Initiative
    Underused opportunityMixedProject-curated
    HCMI-CMDCGDC + IDC805 casesDuctal and Lobular Neoplasms, Complex Mixed and Stromal Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 15.8 months; 10 measurement types on the same cohort

    805 next-generation cancer models - organoids and other patient-derived systems - with whole genome sequencing on 804 and the matched patient tumor, spanning many rare cancers.

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNARadiology imaging+4 more

    6 articles analyzed these data

  • Glioblastoma Multiforme
    MixedProject-curated
    TCGA-GBMGDC + IDC617 casesGliomas, Not Reported

    Why it fits: treatment response recorded; survival endpoints, median follow-up 12.0 months; 12 measurement types on the same cohort

    617 glioblastomas with twelve measurement types including radiology on 607 and pathology slides on 389 - the reference glioma cohort, with a median follow-up of 12.0 months.

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,399 articles analyzed these data - 6,091 cite the paper

  • Ovarian Serous Cystadenocarcinoma
    MixedMachine-extracted
    TCGA-OVGDC + IDC608 casesNot Reported, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.7 years; 11 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNAReverse phase protein array+5 more

    641 articles analyzed these data - 6,322 cite the paper

  • Lung Adenocarcinoma
    MixedMachine-extracted
    TCGA-LUADGDC + IDC585 casesCystic, Mucinous and Serous Neoplasms, Ductal and Lobular Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.6 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    2,831 articles analyzed these data - 4,700 cite the paper

  • Uterine Corpus Endometrial Carcinoma
    MixedMachine-extracted
    TCGA-UCECGDC + IDC560 casesNot Reported, Epithelial Neoplasms, NOS

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.5 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    387 articles analyzed these data - 4,497 cite the paper

  • Kidney Renal Clear Cell Carcinoma
    MixedMachine-extracted
    TCGA-KIRCGDC + IDC537 casesAdenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 3.2 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,245 articles analyzed these data - 2,845 cite the paper

  • Head and Neck Squamous Cell Carcinoma
    MixedMachine-extracted
    TCGA-HNSCGDC + IDC528 casesSquamous Cell Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.2 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    758 articles analyzed these data - 3,314 cite the paper

  • Brain Lower Grade Glioma
    MixedMachine-extracted
    TCGA-LGGGDC + IDC516 casesGliomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 22.3 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    620 articles analyzed these data - 2,440 cite the paper

  • Thyroid Carcinoma
    MixedMachine-extracted
    TCGA-THCAGDC + IDC507 casesEpithelial Neoplasms, NOS, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.6 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    363 articles analyzed these data - 2,365 cite the paper

  • Lung Squamous Cell Carcinoma
    MixedMachine-extracted
    TCGA-LUSCGDC + IDC504 casesAdenomas and Adenocarcinomas, Squamous Cell Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.7 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    643 articles analyzed these data - 3,276 cite the paper

  • Prostate Adenocarcinoma
    MixedMachine-extracted
    TCGA-PRADGDC + IDC500 casesAdenomas and Adenocarcinomas, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.5 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    997 articles analyzed these data - 2,610 cite the paper

  • Skin Cutaneous Melanoma
    MixedMachine-extracted
    TCGA-SKCMGDC + IDC470 casesNevi and Melanomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 3.0 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    724 articles analyzed these data - 2,530 cite the paper

  • Colon Adenocarcinoma
    MixedMachine-extracted
    TCGA-COADGDC + IDC464 casesEpithelial Neoplasms, NOS, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.6 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,838 articles analyzed these data - 6,963 cite the paper

  • Stomach Adenocarcinoma
    MixedMachine-extracted
    TCGA-STADGDC + IDC443 casesAdenomas and Adenocarcinomas, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 13.9 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    1,405 articles analyzed these data - 5,063 cite the paper

  • Bladder Urothelial Carcinoma
    MixedMachine-extracted
    TCGA-BLCAGDC + IDC412 casesEpithelial Neoplasms, NOS, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 17.5 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    894 articles analyzed these data - 2,361 cite the paper

  • Burkitt Lymphoma Genome Sequencing Project
    Underused opportunityMixedMachine-extracted
    CGCI-BLGSPGDC + IDC388 casesMature B-Cell Lymphomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 15.7 months; 9 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesmicroRNARadiology imagingBulk RNA sequencing+3 more

    5 articles analyzed these data

  • Liver Hepatocellular Carcinoma
    MixedMachine-extracted
    TCGA-LIHCGDC + IDC377 casesAdenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 19.7 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    2,568 articles analyzed these data - 2,049 cite the paper

  • Metastatic Bladder Urothelial Carcinoma (IMvigor210 Phase II Trial, ESMO Open. 2024) - iAtlas Harmonized
    OpenMachine-extracted
    blca_iatlas_imvigor210_2017cBioPortal347 casesBladder Urothelial Carcinoma

    Why it fits: treatment response recorded; survival endpoints, median follow-up 8.1 months; no access request needed

    Bulk RNA sequencingTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
    MixedMachine-extracted
    TCGA-CESCGDC + IDC307 casesAdenomas and Adenocarcinomas, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 21.0 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    416 articles analyzed these data - 1,245 cite the paper

  • Kidney Renal Papillary Cell Carcinoma
    MixedMachine-extracted
    TCGA-KIRPGDC + IDC291 casesAdenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.1 years; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    163 articles analyzed these data - 1,012 cite the paper

  • Appendiceal Cancer (MSK, J Clin Oncol 2022)
    OpenMachine-extracted
    appendiceal_msk_2022cBioPortal273 casesAppendiceal Adenocarcinoma

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.1 years; 3 measurement types on the same cohort

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Center for Cancer Genomics (CCG) Cancers of Unknown Primary Project (CUPP)
    MixedMachine-extracted
    CCG-CUPPGDC272 casesDuctal and Lobular Neoplasms, Transitional Cell Papillomas and Carcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 6.5 months; 9 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNABulk RNA sequencing+3 more

    0 articles analyzed these data

  • Renal Cell Carcinoma (IMmotion150 Clinical Trial, Nat Med. 2018) - iAtlas Harmonized
    OpenMachine-extracted
    rcc_iatlas_immotion150_2018cBioPortal263 casesRenal Cell Carcinoma

    Why it fits: treatment response recorded; survival endpoints, median follow-up 5.8 months; no access request needed

    Bulk RNA sequencingTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Testicular Germ Cell Tumors
    MixedMachine-extracted
    TCGA-TGCTGDC + IDC263 casesGerm Cell Neoplasms

    Why it fits: treatment response recorded; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    53 articles analyzed these data - 359 cite the paper

  • HIV+ Tumor Molecular Characterization Project - Cervical Cancer
    MixedProject-curated
    CGCI-HTMCP-CCGDC + IDC212 casesEpithelial Neoplasms, NOS, Adenomas and Adenocarcinomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 13.2 months; 10 measurement types on the same cohort

    212 cervical carcinomas from Ugandan women, 98% Black African and enriched for HIV infection - the largest genomically characterized cervical cancer cohort from sub-Saharan Africa, with ECOG status on 99% of cases, treatment outcome on 68%, and a derivable follow-up time for every single case.

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNARadiology imaging+4 more

    21 articles analyzed these data - 70 cite the paper

  • CPTAC STAD Study
    Underused opportunityOpenProject-curated
    PDC000622PDC193 casesStomach Adenocarcinoma, Early Onset Gastric Cancer

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.0 years; 7 measurement types on the same cohort

    193 gastric cancers measured seven ways - proteome, phosphoproteome, acetylome, glycoproteome, ubiquitylome, metabolome and protein-protein interaction - the deepest single-cohort molecular characterization in the NCI portfolio, and openly downloadable.

    AcetylomeGlycoproteomeMetabolomeOtherPhosphoproteomeProteome (mass spectrometry)+1 more

    1 article analyzed these data

  • Esophageal Carcinoma
    MixedMachine-extracted
    TCGA-ESCAGDC + IDC185 casesAdenomas and Adenocarcinomas, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 13.1 months; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    308 articles analyzed these data - 1,428 cite the paper

  • Pancreatic Adenocarcinoma
    MixedMachine-extracted
    TCGA-PAADGDC + IDC185 casesEpithelial Neoplasms, NOS, Ductal and Lobular Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 15.3 months; 11 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNAReverse phase protein array+5 more

    854 articles analyzed these data - 1,705 cite the paper

  • Pheochromocytoma and Paraganglioma
    MixedMachine-extracted
    TCGA-PCPGGDC + IDC179 casesParagangliomas and Glomus Tumors

    Why it fits: treatment response recorded; 12 measurement types on the same cohort

    ATAC sequencingClinical dataCopy numberHistopathology slidesDNA methylationmicroRNA+6 more

    43 articles analyzed these data - 638 cite the paper

  • Rectum Adenocarcinoma
    MixedMachine-extracted
    TCGA-READGDC + IDC172 casesAdenomas and Adenocarcinomas, Cystic, Mucinous and Serous Neoplasms

    Why it fits: treatment response recorded; survival endpoints, median follow-up 20.0 months; 11 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNAReverse phase protein array+5 more

    482 articles analyzed these data - 6,963 cite the paper

  • CPTAC AML Study
    OpenProject-curated
    PDC000558PDC164 casesAcute Myeloid Leukemia

    Why it fits: treatment response recorded; survival endpoints, median follow-up 12.1 months; 6 measurement types on the same cohort

    164 acute myeloid leukaemias with proteome, phosphoproteome, acetylome and glycoproteome, plus lipidomics and metabolomics on 98 - one of only three NCI cohorts carrying lipidomic data, openly downloadable.

    AcetylomeGlycoproteomeLipidomeMetabolomePhosphoproteomeProteome (mass spectrometry)

    0 articles analyzed these data

  • Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)
    OpenMachine-extracted
    hcc_mskimpact_2018cBioPortal127 casesHepatocellular Carcinoma

    Why it fits: treatment response recorded; 3 measurement types on the same cohort; no access request needed

    Copy numberStructural variantsTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • Thymoma
    MixedMachine-extracted
    TCGA-THYMGDC + IDC124 casesThymic Epithelial Neoplasms

    Why it fits: treatment response recorded; 11 measurement types on the same cohort

    Clinical dataCopy numberHistopathology slidesDNA methylationmicroRNAReverse phase protein array+5 more

    41 articles analyzed these data - 318 cite the paper

  • CPTAC HNSCC Discovery Study
    OpenMachine-extracted
    PDC000222PDC124 casesHead and Neck Squamous Cell Carcinoma

    Why it fits: treatment response recorded; survival endpoints, median follow-up 2.0 years; no access request needed

    PhosphoproteomeProteome (mass spectrometry)

    18 articles analyzed these data

  • Metastatic Melanoma (DFCI, Nat Med. 2019) - iAtlas Harmonized
    OpenMachine-extracted
    mel_iatlas_liu_2019cBioPortal122 casesMelanoma

    Why it fits: treatment response recorded; survival endpoints, median follow-up 17.5 months; no access request needed

    Bulk RNA sequencingTargeted DNA panel

    No citable accession, so reuse cannot be traced

  • CPTAC GBM Confirmatory Study
    OpenMachine-extracted
    PDC000450PDC118 casesGlioblastoma, Gliomas

    Why it fits: treatment response recorded; survival endpoints, median follow-up 14.4 months; 6 measurement types on the same cohort

    AcetylomeGlycoproteomeLipidomeMetabolomePhosphoproteomeProteome (mass spectrometry)

    0 articles analyzed these data